Fast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS/MS

dc.contributor.authorLam, Anh K.
dc.contributor.authorZhang, Junping
dc.contributor.authorFrabutt, Dylan
dc.contributor.authorMulcrone, Patrick L.
dc.contributor.authorLi, Lei
dc.contributor.authorZeng, Lifan
dc.contributor.authorHerzog, Roland W.
dc.contributor.authorXiao, Weidong
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2023-09-07T15:52:45Z
dc.date.available2023-09-07T15:52:45Z
dc.date.issued2022-09-24
dc.description.abstractAdeno-associated virus (AAV) has emerged as a leading platform for gene therapy. With the skyrocketing rate of AAV research and the prevalence of many new engineered capsids being investigated in preclinical and clinical trials, capsid characterization plays a vital role in serotype confirmation and quality control. Further, peptide mapping the capsid proteins might inevitably be a future requirement by regulatory agencies since it is a critical step in good manufacturing practice (GMP) for biotherapeutic characterization. To overcome many challenges that traditional methods like SDS-PAGE and western blots carry, liquid chromatography and mass spectrometry (LC-MS) allows high resolution and sensitivity with great accuracy in characterizing the AAV capsid proteins. Our optimized LC-MS method provides quick sample preparation, a fast and high-throughput 4-min run, and high sensitivity, which allows for very efficient characterization of wild-type and engineered capsids. This study also reports the usage of LC-MS/MS peptide mapping of AAV capsid proteins to determine the most accessible lysine residues targeted by chemical modifications. Our detailed protocols are anticipated to promote the development and discovery of AAV variants with high accuracy and efficiency.
dc.eprint.versionFinal published version
dc.identifier.citationLam AK, Zhang J, Frabutt D, et al. Fast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS/MS. Mol Ther Methods Clin Dev. 2022;27:185-194. Published 2022 Sep 24. doi:10.1016/j.omtm.2022.09.008
dc.identifier.urihttps://hdl.handle.net/1805/35449
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.omtm.2022.09.008
dc.relation.journalMolecular Therapy - Methods & Clinical Development
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourcePMC
dc.subjectAdeno-associated virus (AAV)
dc.subjectCapsid characterization
dc.subjectLiquid chromatography
dc.subjectMass spectrometry
dc.subjectPeptide mapping
dc.subjectEngineered capsids
dc.subjectGene therapy
dc.titleFast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS/MS
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
main.pdf
Size:
2.58 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: